Replies to post #631963 on NorthWest Biotherapeutics Inc (NWBO)

[supersteve13]

It’s the obvious choice for a partner with a checkpoint inhibitor or similar broad-attack immune stimulator. Any tumor type with a medium to high mutational burden (NSCLC, SCLC, bladder, H&N, etc) would be great candidates.

Not to mention patent cliffs. :)